EUCTR2014-001132-10-FRActive, not recruitingNot Applicable
A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson’s Disease Subjects with Levodopa-Induced Dyskinesias
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Enrollment
- 162
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •For a subject to be eligible for participation in this study, all of the following criteria must be met at screening. Subject must:
- •1. Sign an informed consent form (ICF) indicating that they have been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts.
- •2. Have been diagnosed with idiopathic Parkinson's disease as defined by the UK Parkinson's Disease Society Brain Bank criteria.
- •3. Be male or female 30 to 85 years old.
- •4. Have levodopa induced, predictable peak-effect dyskinesia that are considered by the subject to be problematic and/or disabling.
- •5. Have screening serum creatinine level within the normal range for the testing laboratory.
- •6. Have been on stable doses of all oral anti-Parkinson’s medication, including any levodopa preparation, for 30 days and be willing to remain on the same doses throughout the course of the subject’s participation in the trial.
- •7. The subject/caregiver must demonstrate the ability to complete an accurate home diary based on training and evaluation during the screening period.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 46
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 116
Exclusion Criteria
- •A subject will not be eligible for participation in this study if any of the following criteria apply. The subject:
- •1. Is diagnosed with secondary parkinsonian syndrome, such as vascular, post-inflammatory, drug-induced, neoplastic and post-traumatic parkinsonism or any atypical parkinsonian syndrome (e.g., Progressive Supranuclear Palsy, Multi-System Atrophy, etc.)
- •2. Has used amantadine in any dosage or pharmaceutical form within the past 14 days, or has previously interrupted the use of amantadine due to an adverse event
- •3. Is currently using medications that would potentially interfere with the actions of the study medication or outcome variables, including neuroleptics and atypical antipsychotic agents, acetylcholinesterase inhibitors, apomorphine, rimantadine, memantine and dextromethorphan and quinidine if used in combination for treating dyskinesia.
- •4. Has a history of pallidotomy or other ablative surgery for the treatment of PD, or is implanted with a uni- or bilateral deep brain stimulator
- •5. Has any medical condition or past medical history that, in the Investigator's judgment, would increase the risk of exposure to Amantadine HCl Extended Release Tablets or interfere with safety and efficacy evaluations. These include:
- •o seizure disorders or history of seizures other than childhood febrile convulsions
- •o history of glaucoma
- •o current hallucinations
- •o urinary retention
- •o abuse of legal or illegal drugs within the past 12 months
- •6. Has a history of cancer within 5 years of screening that may compromise the life-expectancy of the subject; exceptions are adequately treated non-melanomatous skin cancers, localized bladder cancer, non-metastatic prostate cancer or in situ cervical cancer.
- •7. Has a history or current diagnosis of schizophrenia or bipolar disorder
- •8. Has current diagnosis of inadequately treated Major Depressive Disorder. Subjects who are on stable doses of selective serotonin reuptake inhibitors (SSRIs) or serotonin -norepinephrine reuptake inhibitors (SNRIs) for depression are eligible for the study
- •9. Is at imminent risk of suicide (score of 4 or 5 on the C-SSRS) or had a suicide attempt within 6 months of the screening visit.
- •10. Has a history of, or current diagnosis of Impulse Control Disorder or is judged to be at risk according to the QUIP-RS
- •11. Has an estimated plasma creatinine clearance of <60 mL/min at screening using the Cockroft-Gault equation
- •12. Has a history of or currently has any of the following clinically significant conditions, that in the investigator’s opinion may interfere with the study procedures or compromise the subject’s safety:
- •o Cardiovascular disease
- •o Respiratory disease
- •o Renal disease
- •o Hepatic disease
- •o Gastrointestinal disease
- •13. Upon evaluation at the screening visit, the subject has:
- •o Any clinically significant vital sign, ECG, or laboratory abnormalities
- •o A positive test for human immunodeficiency virus (HIV) antibody of a history of HIV
- •o A positive test for hepatitis B surface antigen unless the positive test followed a recent (<28 days) vaccination for hepatitis B and the vaccination record is available
- •o A positive test for hepatitis C antibody
- •o A positive urine drug test
- •14. The subject is female, and is pregnant or lactating (breastfeeding) at the time of screening or has a positive pregnancy test result pre-dose
- •15. If a sexually active female, is not surgically sterile or at least 2 years post-menopausal, or does not agree to utiliz
Investigators
Similar Trials
Active, not recruiting
Phase 1
A 26 Week Clinical Study to Evaluate the Use of Long-Acting Amantadine to Treat Parkinson's Disease Patients with Abnormal Involuntary Movements caused by LevodopaParkinson's Disease Subjects with Levodopa-Induced DyskinesiasMedDRA version: 17.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-001132-10-ESOsmotica Pharmaceutical Corp.162
Active, not recruiting
Not Applicable
A Multicenter, Randomized, Placebo-controlled, Double-blind Phase 2 Study to Evaluate the Efficacy and Safety of CJC-1295 administered for 12 weeks in HIV-Infected Patients with HIV-associated Visceral ObesityPatients 18 to 65 years old with HIV-associated visceral obesity, on a stableantiviral regimen for at least 6 weeks, with a viral load =1,000 copies/mL andCD4 count =200 cells/mm3, a body mass index (BMI) of =24 and =30 kg/m2,a waist-to-hip ratio of =0.95 in men or =0.90 in women, and a waistcircumference of =90 cm in men or =85 cm in women.EUCTR2005-003797-25-DEConjuChem, Inc.150
Active, not recruiting
Phase 1
Asunercept for the treatment of patients with moderate to severe COVID-19 diseaseModerate to Severe COVID-19 DiseaseMedDRA version: 23.1Level: LLTClassification code 10084401Term: COVID-19 respiratory infectionSystem Organ Class: 100000004862EUCTR2021-006005-30-DEApogenix AG
Active, not recruiting
Phase 1
Asunercept for the treatment of patients with moderate to severe COVID-19 diseaseEUCTR2021-006005-30-ATApogenix AG640
Active, not recruiting
Not Applicable
Effectiveness and Safety of Lubiprostone for Treatment of Opioid-induced Bowel DysfunctioOpioid-induced Bowel DysfunctionMedDRA version: 14.0Level: PTClassification code 10061247Term: Intestinal functional disorderSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-022991-29-GBSucampo Pharma Americas, Inc.420